Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.

Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY.

J Sex Med. 2010 Jul;7(7):2572-82. doi: 10.1111/j.1743-6109.2010.01859.x.

PMID:
20524974
2.

Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.

Permpongkosol S, Tantirangsee N, Ratana-olarn K.

J Sex Med. 2010 Nov;7(11):3765-74. doi: 10.1111/j.1743-6109.2010.01994.x.

PMID:
20807330
3.

A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.

Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, Zainuddin ZM, Tan HM.

BJU Int. 2012 Jul;110(2):260-5. doi: 10.1111/j.1464-410X.2011.10755.x.

4.
5.

The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.

Moon du G, Park MG, Lee SW, Park K, Park JK, Kim SW, Park NC, Ahn TY, Paick JS, Seo JT, Yang DY, Lee JY, Kim JJ.

J Sex Med. 2010 Jun;7(6):2253-60. doi: 10.1111/j.1743-6109.2010.01765.x.

PMID:
20345732
6.
7.
8.

The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).

Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A; Blast Study Group..

Int J Clin Pract. 2014 Feb;68(2):203-15. doi: 10.1111/ijcp.12235.

PMID:
24355040
9.

Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.

Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A.

J Endocrinol Invest. 2010 Dec;33(11):776-83. doi: 10.3275/6903.

PMID:
20220293
10.

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.

Traish AM, Haider A, Doros G, Saad F.

Int J Clin Pract. 2014 Mar;68(3):314-29. doi: 10.1111/ijcp.12319.

11.

Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.

Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M.

J Clin Endocrinol Metab. 2014 Oct;99(10):3821-8. doi: 10.1210/jc.2014-1872.

PMID:
24978674
12.

Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.

Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P; BLAST Study Group..

J Sex Med. 2014 Mar;11(3):840-56. doi: 10.1111/jsm.12404.

PMID:
24308723
13.

A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel.

Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG.

Aging Male. 2014 Mar;17(1):1-11. doi: 10.3109/13685538.2013.858113.

14.

The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.

Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E.

J Sex Med. 2011 Dec;8(12):3471-8. doi: 10.1111/j.1743-6109.2011.02497.x.

PMID:
21995803
15.

Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial.

Amiaz R, Pope HG Jr, Mahne T, Kelly JF, Brennan BP, Kanayama G, Weiser M, Hudson JI, Seidman SN.

J Sex Marital Ther. 2011;37(4):243-54. doi: 10.1080/0092623X.2011.582425.

PMID:
21707327
16.

C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation.

Giltay EJ, Haider A, Saad F, Gooren LJ.

Andrologia. 2008 Dec;40(6):398-400. doi: 10.1111/j.1439-0272.2008.00873.x.

PMID:
19032692
17.

Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.

Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM; Study 43203 Investigators..

Eur J Endocrinol. 2009 May;160(5):821-31. doi: 10.1530/EJE-08-0634.

18.

Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men.

Hintikka J, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Lehto SM, Viinamäki H.

J Sex Med. 2009 Jul;6(7):2049-57. doi: 10.1111/j.1743-6109.2009.01299.x.

PMID:
19453895
19.
20.

Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.

Saad F, Gooren L, Haider A, Yassin A.

Andrologia. 2008 Feb;40(1):44-8. doi: 10.1111/j.1439-0272.2008.00807.x.

PMID:
18211301
Items per page

Supplemental Content

Support Center